Tag: newswire

SINGAPORE, June 17, 2026 (GLOBE NEWSWIRE) -- China's largest international entrepreneurship platform is setting its sights on Singapore, positioning the city-state as its gateway to Southeast Asia. HICOOL 2026 Global Startup Competition wrapped up its Singapore leg on June 4-5 at NUS, drawing nearly 40 teams from China, Singapore, Indonesia, Thailand, Japan, South Korea, India, France, Switzerland, Germany, and beyond. HICOOL has run its Singapore leg for two consecutive years, enabling Singapore's innovation ecosystem and China's industrial landscape to empower each other — creating a genuine two-way flow of technology and markets.

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Legend Biotech, are expected to be approximately $226 million, excluding any proceeds from the exercise of the underwriters’ option to purchase additional ADSs. The offering is expected to close on June 23, 2026, subject to customary closing conditions.

WEST VANCOUVER, British Columbia, June 17, 2026 (GLOBE NEWSWIRE) -- The Brick is proud to announce Canadian soccer superstar Alphonso Davies as its newest brand ambassador and is celebrating the launch of the partnership with an exclusive fan meet and greet at its Park Royal location in West Vancouver on Saturday, June 20, 2026.

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Lucid Group, Inc. (“Lucid” or the “Company”) (NASDAQ:LCID) investors of the July 28, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

New York health technology company combines general wellness, mental health, and nutrition AI into a single personalized ecosystem - and prepares its Vital IQ™ wearable for market

Sydney, Australia, June 17, 2026 (GLOBE NEWSWIRE) -- Australian superannuation regulations require self-managed super funds to maintain a documented investment strategy that covers asset allocation, liquidity, diversification, and both income and capital objectives. The Australian Taxation Office mandates that the strategy be reviewed at least annually. For trustees building that strategy around delivering monthly income, the income side of the portfolio will be reviewed closely. The latest ATO data shows the SMSF sector now holds A$1.06 trillion in assets across 663,867 funds, with cash and term deposit allocations falling to 16.3% of holdings, a record low, as trustees look beyond traditional cash products. To learn mroe visit https://termplus.com.au/term-account-smsf/

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Calix, Inc. (“Calix” or the “Company”) (NYSE:CALX) investors of the July 27, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions.

Acquisition adds multiple immunology assets to Biogen’s portfolio, including a lead asset poised to enter Phase 1 development